Trial · NCT02062905
OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
NCT02062905, Phase 2, Completed, Ocular Therapeutix, Inc.; results first posted 2016-05-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis. Trials, record NCT02062905. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02062905
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
- NCT number
- NCT02062905
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 68 participants, actual
- Lead sponsor
- Ocular Therapeutix, Inc.
- Conditions
- Chronic Allergic Conjunctivitis
- Interventions
- Dexamethasone, Placebo Vehicle
- First posted
- 2014-02-14
- Last updated
- 2019-09-11
- Results first posted
- 2016-05-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ocular Itching | 14 days post insertion | Proprietary Ora Calibra Conjunctival Allergen Challenge Ocular Itching Scale (0 - 4 with 0.5 unit increments allowed; "0" = no itching) |
| Secondary | Conjunctival Redness | 14 days post insertion | Proprietary Ora Calibra Ocular Hyperemia Scale (0 - 4 with 0.5 unit increments allowed; "0" = no redness) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Ocular Itching | 14 days post insertion | units on a scale (0 -4) | MEAN | |
| SECONDARY | Conjunctival Redness | 14 days post insertion | units on a scale (0 - 4) | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ocular Itching | OTX-DP Treatment | 3 min (14 days post-insertion) | 1.80 | Standard Deviation 1.068 | units on a scale (0 -4) |
| Ocular Itching | Placebo Plug Delivery Vehicle | 3 min (14 days post-insertion) | 2.58 | Standard Deviation 0.823 | units on a scale (0 -4) |
| Ocular Itching | OTX-DP Treatment | 5 min. (14 days post-insertion) | 1.72 | Standard Deviation 0.998 | units on a scale (0 -4) |
| Ocular Itching | Placebo Plug Delivery Vehicle | 5 min. (14 days post-insertion) | 2.70 | Standard Deviation 0.865 | units on a scale (0 -4) |
| Ocular Itching | OTX-DP Treatment | 7 min. (14 days post-insertion) | 1.65 | Standard Deviation 0.989 | units on a scale (0 -4) |
| Ocular Itching | Placebo Plug Delivery Vehicle | 7 min. (14 days post-insertion) | 2.53 | Standard Deviation 0.880 | units on a scale (0 -4) |
| Conjunctival Redness | OTX-DP Treatment | 7 min. (14 days post-insertion) | 1.60 | Standard Deviation 0.753 | units on a scale (0 - 4) |
| Conjunctival Redness | Placebo Plug Delivery Vehicle | 7 min. (14 days post-insertion) | 2.11 | Standard Deviation 0.727 | units on a scale (0 - 4) |
| Conjunctival Redness | OTX-DP Treatment | 15 min. (14 days post-insertion) | 1.53 | Standard Deviation 0.753 | units on a scale (0 - 4) |
| Conjunctival Redness | Placebo Plug Delivery Vehicle | 15 min. (14 days post-insertion) | 2.23 | Standard Deviation 0.708 | units on a scale (0 - 4) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | OTX-DP Treatment | 35 | |
| Overall Study | STARTED | Placebo Plug Delivery Vehicle | 33 | |
| Overall Study | COMPLETED | OTX-DP Treatment | 28 | |
| Overall Study | COMPLETED | Placebo Plug Delivery Vehicle | 31 | |
| Overall Study | NOT COMPLETED | OTX-DP Treatment | 7 | |
| Overall Study | NOT COMPLETED | Placebo Plug Delivery Vehicle | 2 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | eye discharge | Eye disorders | OTX-DP Treatment | 1 | 31 | 1 |
| other | eye discharge | Eye disorders | Placebo Plug Delivery Vehicle | 2 | 33 | 2 |
| serious | depression | Psychiatric disorders | OTX-DP Treatment | 1 | 31 | 1 |
| serious | depression | Psychiatric disorders | Placebo Plug Delivery Vehicle | 0 | 33 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | OTX-DP Treatment | ||
| Total, all-cause mortality | Placebo Plug Delivery Vehicle | ||
| Total, other adverse events | OTX-DP Treatment | 1 | 31 |
| Total, other adverse events | Placebo Plug Delivery Vehicle | 2 | 33 |
| Total, serious adverse events | OTX-DP Treatment | 1 | 31 |
| Total, serious adverse events | Placebo Plug Delivery Vehicle | 0 | 33 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| OTX-DP Treatment vs Placebo Plug Delivery Vehicle: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02062905
GET https://conductscience.org/api/trials/v1/NCT02062905/registered